Ambroxol in the 21st century: pharmacological and clinical update

Malerba, Mario; Ragnoli, Beatrice

doi:10.1517/17425255.4.8.1119

Cited by 155 publications

(147 citation statements)

References 56 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Ambroxol-HCl (trans-4[2-amino-3.5-dibrombenzylamino]-cyclohexanhydro-chloride), which stimulates the release of surfactant production by type II pneumocytes and reduces bronchial hyper-reactivity, is used clinically as a mucolytic agent or expectorant in the treatment of chronic bronchitis (8). But recent research has demonstrated that ambroxol, efficiently scavenges reactive oxygen species and that it has anti-inflammatory properties (9,10).…”

Section: Introductionmentioning

confidence: 99%

Protective Effect of Ambroxol against Paraquat-induced Pulmonary Fibrosis in Rats

2011

View full text Add to dashboard Cite

Objective To evaluate the possible therapeutic effect of ambroxol on pulmonary fibrosis induced by paraquat. Methods Adult male Sprague-Dawley rats (n =144, 200-250 g) were divided into four groups (Control, Ambroxol, Paraquat, and Paraquat+Ambroxol group) and sacrificed on day 1, 3, 5, 7, 14 and 28. Several significant oxidant stress markers (MDA, SOD and GSH-PX), MPO activity, cytokines (TNF-α, MCP-1, TGF-β1, MMP-2 and TIMP-1), total inflammatory cell count, hydroxyproline content, collagen I and III mRNA were analyzed. Results In Paraquat group, the MDA, MPO activity, hydroxyproline contents, the mRNA expression of TNF-α, MCP-1, TGF-β1, MMP-2, TIMP-1, collagen I, collagen III and the number of total inflammatory cells were up-regulated in lung tissue, but SOD and GSH-PX activity were down-regulated in lung tissue compared with Control group (p<0.05). In paraquat+ambroxol group, the MDA, MPO activity, hydroxyproline content, the mRNA expression of TNF-α, MCP-1, TGF-β1, MMP-2, TIMP-1 collagen I, collagen III and the number of total inflammatory cells were significantly decreased, while the SOD and GSH-PX activities in lung tissue were increased compared with Paraquat group (p<0.05). Histological examination of paraquat-treated rats showed lung injury with interstitial edema and widespread inflammatory cell infiltration in the alveolar space and septum, as well as pulmonary fibrosis. Ambroxol could markedly reduce such damage in lung tissue and prevent pulmonary fibrosis. Conclusion The results of this study indicated that ambroxol could reduce lung damage and prevent pulmonary fibrosis induced by paraquat.

show abstract

Section: Introductionmentioning

confidence: 99%

Protective Effect of Ambroxol against Paraquat-induced Pulmonary Fibrosis in Rats

2011

View full text Add to dashboard Cite

show abstract

“…Широко применяемый секретолитический пре-парат амброксол относится к эффективным мукоак-тивным препаратам нового поколения [27]. Амброк-сол является активным метаболитом бромгексина и потому значительно его эффективнее.…”

Section: обзоры литературыunclassified

“…Препарат можно использовать у детей любого возраста, даже у недоно-шенных [27,37]. Амброксол и бромгексин противо-показаны при судорожном синдроме.…”

Section: российский вестник перинатологии и педиатрии 4 2016 Rossiyunclassified

Differentiation mucolytic therapy for acute and chronic bronchopulmonary diseases in pediatric practice

Мизерницкий¹,

Мельникова²

2016

Ross. vestn. perinatol. pediatr.

View full text Add to dashboard Cite

“…bronchitis) and chronic respiratory diseases (e.g. COPD) [1][2][3]. Pharmacological and clinical studies showed the mucoregulative and secretagogue properties of ambroxol [4].…”

Section: Introductionmentioning

confidence: 99%

More than Expectorant: New Scientific Data on Ambroxol in the Context of the Treatment of Bronchopulmonary Diseases

Plomer

Zeeuw

2017

J Intensive Crit Care

View full text Add to dashboard Cite

show abstract

Ambroxol in the 21st century: pharmacological and clinical update

Cited by 155 publications

References 56 publications

Protective Effect of Ambroxol against Paraquat-induced Pulmonary Fibrosis in Rats

Protective Effect of Ambroxol against Paraquat-induced Pulmonary Fibrosis in Rats

Differentiation mucolytic therapy for acute and chronic bronchopulmonary diseases in pediatric practice

More than Expectorant: New Scientific Data on Ambroxol in the Context of the Treatment of Bronchopulmonary Diseases

Contact Info

Product

Resources

About